

# Daniel F Alonso

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2682637/publications.pdf>

Version: 2024-02-01

120  
papers

3,305  
citations

136950  
32  
h-index

182427  
51  
g-index

120  
all docs

120  
docs citations

120  
times ranked

3345  
citing authors

#	ARTICLE	IF	CITATIONS
1	Desmopressin in canine mammary carcinoma: Comments on the importance of the administration route. <i>Veterinary and Comparative Oncology</i> , 2021, 19, 409-410.	1.8	1
2	Anticancer activity of repurposed hemostatic agent desmopressin on AVPR2-expressing human osteosarcoma. <i>Experimental and Therapeutic Medicine</i> , 2021, 21, 566.	1.8	7
3	Antiviral effect of high-dose ivermectin in adults with COVID-19: A proof-of-concept randomized trial. <i>EClinicalMedicine</i> , 2021, 37, 100959.	7.1	66
4	Effect of Ivermectin and Atorvastatin on Nuclear Localization of Importin Alpha and Drug Target Expression Profiling in Host Cells from Nasopharyngeal Swabs of SARS-CoV-2- Positive Patients. <i>Viruses</i> , 2021, 13, 2084.	3.3	8
5	Repurposing of host-based therapeutic agents for the treatment of coronavirus disease 2019 (COVID-19): a link between antiviral and anticancer mechanisms?. <i>International Journal of Antimicrobial Agents</i> , 2020, 56, 106125.	2.5	7
6	Preclinical efficacy of CIGB-300, an anti-CK2 peptide, on breast cancer metastatic colonization. <i>Scientific Reports</i> , 2020, 10, 14689.	3.3	12
7	<i>In vitro</i> and <i>in vivo</i> antitumor activity of Yerba Mate extract in colon cancer models. <i>Journal of Food Science</i> , 2020, 85, 2186-2197.	3.1	18
8	Administration of the vasopressin analog desmopressin for the management of bleeding in rectal cancer patients: results of a phase I/II trial. <i>Investigational New Drugs</i> , 2020, 38, 1580-1587.	2.6	3
9	Development and therapeutic potential of vasopressin synthetic analog [V4Q5]dDAVP as a novel anticancer agent. <i>Vitamins and Hormones</i> , 2020, 113, 259-289.	1.7	4
10	Minimally disseminated disease and outcome in overt orbital retinoblastoma. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27662.	1.5	3
11	Potential Use of Desmopressin During Hepatic Resection for Colorectal Liver Metastases*. <i>Journal of Surgical Research</i> , 2019, 237, 1-2.	1.6	2
12	Commentary: Arginine vasopressin receptor 1a is a therapeutic target for castration-resistant prostate cancer. <i>Frontiers in Oncology</i> , 2019, 9, 1490.	2.8	6
13	Preclinical Efficacy of [V4 Q5 ]dDAVP, a Second Generation Vasopressin Analog, on Metastatic Spread and Tumor-Associated Angiogenesis in Colorectal Cancer. <i>Cancer Research and Treatment</i> , 2019, 51, 438-450.	3.0	15
14	Search of vasopressin analogs with antiproliferative activity on small-cell lung cancer: drug design based on two different approaches. <i>Future Medicinal Chemistry</i> , 2018, 10, 879-894.	2.3	5
15	Relevance of small GTPase Rac1 pathway in drug and radio-resistance mechanisms: Opportunities in cancer therapeutics. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 124, 29-36.	4.4	35
16	Impact of Perioperative Blood Transfusion on Survival Among Women With Breast Cancer: Potential Benefits of Blood-Saving Agent Desmopressin Use During Surgery. <i>American Journal of Therapeutics</i> , 2018, 25, e569-e570.	0.9	2
17	<i>In vitro</i> and <i>in vivo</i> evaluation of desmopressin-loaded poly(D,L-lactic-co-glycolic acid) nanoparticles for its potential use in cancer treatment. <i>Nanomedicine</i> , 2018, 13, 2835-2849.	3.3	4
18	Antibody-dependent cell-mediated cytotoxicity induced by active immunotherapy based on racotumomab in non-small cell lung cancer patients. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 1285-1296.	4.2	21

#	ARTICLE	IF	CITATIONS
19	Minimal disseminated disease evaluation and outcome in trilateral retinoblastoma. British Journal of Ophthalmology, 2018, 102, 1597-1601.	3.9	4
20	Aberrant O-glycosylation modulates aggressiveness in neuroblastoma. Oncotarget, 2018, 9, 34176-34188.	1.8	4
21	CIGB-300, an anti-CK2 peptide, inhibits angiogenesis, tumor cell invasion and metastasis in lung cancer models. Lung Cancer, 2017, 107, 14-21.	2.0	30
22	Pharmacological inhibition of Rac1-PAK1 axis restores tamoxifen sensitivity in human resistant breast cancer cells. Cellular Signalling, 2017, 30, 154-161.	3.6	32
23	Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Colorectal Cancer: Potential use of Perioperative Desmopressin to Reduce Allogenic Blood Transfusion Rates. Journal of Gastrointestinal Surgery, 2017, 21, 1971-1973.	1.7	1
24	Peptide Agonists of Vasopressin V2 Receptor Reduce Expression of Neuroendocrine Markers and Tumor Growth in Human Lung and Prostate Tumor Cells. Frontiers in Oncology, 2017, 7, 11.	2.8	24
25	Perioperative biology in primary breast cancer: selective targeting of vasopressin type 2 receptor using desmopressin as a novel therapeutic approach. Breast Cancer Research and Treatment, 2016, 158, 597-599.	2.5	5
26	Comparability of Antibody-Mediated Cell Killing Activity Between a Proposed Biosimilar RTX83 and the Originator Rituximab. BioDrugs, 2016, 30, 225-231.	4.6	17
27	Addition of vasopressin synthetic analogue [V4Q5]dDAVP to standard chemotherapy enhances tumour growth inhibition and impairs metastatic spread in aggressive breast tumour models. Clinical and Experimental Metastasis, 2016, 33, 589-600.	3.3	12
28	Urokinase Exerts Antimetastatic Effects by Dissociating Clusters of Circulating Tumor Cells Letter. Cancer Research, 2016, 76, 4908-4908.	0.9	2
29	Minimal Disseminated Disease in Nonmetastatic Retinoblastoma With High-Risk Pathologic Features and Association With Disease-Free Survival. JAMA Ophthalmology, 2016, 134, 1374.	2.5	21
30	Racotumomab for treating lung cancer and pediatric refractory malignancies. Expert Opinion on Biological Therapy, 2016, 16, 573-578.	3.1	18
31	A phase II dose-escalation trial of perioperative desmopressin (1-desamino-8-d-arginine vasopressin) in breast cancer patients. SpringerPlus, 2015, 4, 428.	1.2	34
32	The novel desmopressin analogue [V4Q5]dDAVP inhibits angiogenesis, tumour growth and metastases in vasopressin type 2 receptor-expressing breast cancer models. International Journal of Oncology, 2015, 46, 2335-2345.	3.3	28
33	A Phase I Study of the Anti-Idiotypic Vaccine Racotumomab in Neuroblastoma and Other Pediatric Refractory Malignancies. Pediatric Blood and Cancer, 2015, 62, 2120-2124.	1.5	34
34	Optimizing CIGB-300 intralesional delivery in locally advanced cervical cancer. British Journal of Cancer, 2015, 112, 1636-1643.	6.4	32
35	Association of Cone-Rod Homeobox Transcription Factor Messenger RNA With Pediatric Metastatic Retinoblastoma. JAMA Ophthalmology, 2015, 133, 805.	2.5	28
36	RAC3 more than a nuclear receptor coactivator: a key inhibitor of senescence that is downregulated in aging. Cell Death and Disease, 2015, 6, e1902-e1902.	6.3	14

#	ARTICLE	IF	CITATIONS
37	CIGB-300: A Promising Anti-Casein Kinase 2 (CK2) Peptide for Cancer Targeted Therapy. , 2015, , 281-298.		2
38	Cirrhosis, von Willebrand Factor (vWF) and the Low Incidence of Metastatic Malignancy in Injured Liver. Eurasian Journal of Medicine, 2015, 47, 229-230.	0.6	0
39	Preclinical Development of Novel Rac1-GEF Signaling Inhibitors using a Rational Design Approach in Highly Aggressive Breast Cancer Cell Lines. Anti-Cancer Agents in Medicinal Chemistry, 2014, 14, 840-851.	1.7	67
40	Proapoptotic and antiinvasive activity of Rac1 small molecule inhibitors on malignant glioma cells. OncoTargets and Therapy, 2014, 7, 2021.	2.0	26
41	Mechanisms of Cellular Uptake, Intracellular Transportation, and Degradation of CIGB-300, a Tat-Conjugated Peptide, in Tumor Cell Lines. Molecular Pharmaceutics, 2014, 11, 1798-1807.	4.6	18
42	Structure-activity relationship of 1-desamino-8-D-arginine vasopressin as an antiproliferative agent on human vasopressin V2 receptor-expressing cancer cells. Molecular Medicine Reports, 2014, 9, 2568-2572.	2.4	13
43	Insight into the effect of the vasopressin analog desmopressin on lung colonization by mammary carcinoma cells in BALB/c mice. Anticancer Research, 2014, 34, 4761-5.	1.1	13
44	Detection of minimally disseminated disease in the cerebrospinal fluid of children with high-risk retinoblastoma by reverse transcriptase-polymerase chain reaction for GD2 synthase mRNA. European Journal of Cancer, 2013, 49, 2892-2899.	2.8	26
45	Reduction of tumor angiogenesis induced by desmopressin in a breast cancer model. Breast Cancer Research and Treatment, 2013, 142, 9-18.	2.5	34
46	Implication of von Willebrand Factor as a Regulator of Tumor Cell Metastasis: Potential Perioperative Use of Desmopressin and Novel Peptide Analogs. Acta Haematologica, 2013, 129, 223-224.	1.4	4
47	Anti-idiotypic antibodies in cancer treatment. Frontiers in Oncology, 2013, 3, 37.	2.8	2
48	Preclinical evaluation of racotumomab, an anti-idiotypic monoclonal antibody to N-glycolyl-containing gangliosides, with or without chemotherapy in a mouse model of non-small cell lung cancer. Frontiers in Oncology, 2012, 2, 160.	2.8	16
49	AZT as a telomerase inhibitor. Frontiers in Oncology, 2012, 2, 113.	2.8	45
50	Racotumomab: an anti-idiotypic vaccine related to N-glycolyl-containing gangliosides “ preclinical and clinical data. Frontiers in Oncology, 2012, 2, 150.	2.8	30
51	Re: Effect of ADAM28 on Carcinoma Cell Metastasis by Cleavage of von Willebrand Factor. Journal of the National Cancer Institute, 2012, 104, 1917-1917.	6.3	0
52	Cancer Antigen Prioritization: A Road Map to Work in Defining Vaccines Against Specific Targets. A Point of View. Frontiers in Oncology, 2012, 2, 66.	2.8	9
53	Telomere structure and telomerase in health and disease. International Journal of Oncology, 2012, 41, 1561-1569.	3.3	126
54	Sensitivity of tumor cells towards CIGB-300 anticancer peptide relies on its nucleolar localization. Journal of Peptide Science, 2012, 18, 215-223.	1.4	28

#	ARTICLE	IF	CITATIONS
55	Anti-ganglioside antibodies induced in chickens by an alum-adsorbed anti-idiotypic antibody targeting NeuGcGM3. <i>Frontiers in Immunology</i> , 2012, 3, 422.	4.8	3
56	The Functional Interaction between Acyl-CoA Synthetase 4, 5-Lipoxygenase and Cyclooxygenase-2 Controls Tumor Growth: A Novel Therapeutic Target. <i>PLoS ONE</i> , 2012, 7, e40794.	2.5	51
57	Antitumor protection by NGcGM3/VSSP vaccine against transfected B16 mouse melanoma cells overexpressing N-glycosylated gangliosides. <i>In Vivo</i> , 2012, 26, 609-17.	1.3	14
58	Effect of atorvastatin in a case of feline multicentric lymphoma " Case report. <i>Acta Veterinaria Hungarica</i> , 2011, 59, 69-76.	0.5	0
59	Effect of Adjuvant Perioperative Desmopressin in Locally Advanced Canine Mammary Carcinoma and its Relation to Histologic Grade. <i>Journal of the American Animal Hospital Association</i> , 2011, 47, 21-27.	1.1	32
60	CIGB-300, a proapoptotic peptide, inhibits angiogenesis in vitro and in vivo. <i>Experimental Cell Research</i> , 2011, 317, 1677-1688.	2.6	20
61	Antiproliferative effect of 1-deamino-8-D-arginine vasopressin analogs on human breast cancer cells. <i>Future Medicinal Chemistry</i> , 2011, 3, 1987-1993.	2.3	28
62	CIGB-300, a synthetic peptide-based drug that targets the CK2 phosphoacceptor domain. Translational and clinical research. <i>Molecular and Cellular Biochemistry</i> , 2011, 356, 45-50.	3.1	41
63	Immunoreactivity of the 14F7 Mab Raised against N-Glycolyl GM3 Ganglioside in Epithelial Malignant Tumors from Digestive System. <i>ISRN Gastroenterology</i> , 2011, 2011, 1-8.	1.5	32
64	Tissue factor as a novel marker for detection of circulating cancer cells. <i>Biomarkers</i> , 2011, 16, 58-64.	1.9	6
65	Detection of N-Glycolyl GM3 Ganglioside in Neuroectodermal Tumors by Immunohistochemistry: An Attractive Vaccine Target for Aggressive Pediatric Cancer. <i>Clinical and Developmental Immunology</i> , 2011, 2011, 1-6.	3.3	45
66	Combined therapeutic effect of a monoclonal anti-idiotypic tumor vaccine against NeuGc-containing gangliosides with chemotherapy in a breast carcinoma model. <i>Breast Cancer Research and Treatment</i> , 2010, 120, 379-389.	2.5	31
67	NGcGM3 Ganglioside: A Privileged Target for Cancer Vaccines. <i>Clinical and Developmental Immunology</i> , 2010, 2010, 1-8.	3.3	67
68	Detection and Characterization of N-Glycosylated Gangliosides in Wilms Tumor by Immunohistochemistry. <i>Pediatric and Developmental Pathology</i> , 2010, 13, 18-23.	1.0	38
69	Direct validation of NGcGM3 ganglioside as a new target for cancer immunotherapy. <i>Expert Opinion on Biological Therapy</i> , 2010, 10, 153-162.	3.1	32
70	Proteomic Profile Regulated by the Anticancer Peptide CIGB-300 in Non-Small Cell Lung Cancer (NSCLC) Cells. <i>Journal of Proteome Research</i> , 2010, 9, 5473-5483.	3.7	26
71	Optimization of molecular detection of GD2 synthase mRNA in retinoblastoma. <i>Molecular Medicine Reports</i> , 2010, 3, 253-9.	2.4	18
72	Effects of the synthetic vasopressin analog desmopressin in a mouse model of colon cancer. <i>Anticancer Research</i> , 2010, 30, 5049-54.	1.1	16

#	ARTICLE	IF	CITATIONS
73	Anticancer peptide CIGB-300 binds to nucleophosmin/B23, impairs its CK2-mediated phosphorylation, and leads to apoptosis through its nucleolar disassembly activity. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 1189-1196.	4.1	62
74	Safety and preliminary efficacy data of a novel Casein Kinase 2 (CK2) peptide inhibitor administered intralesionally at four dose levels in patients with cervical malignancies. <i>BMC Cancer</i> , 2009, 9, 146.	2.6	64
75	Exogenous incorporation of neugc-rich mucin augments n-glycolyl sialic acid content and promotes malignant phenotype in mouse tumor cell lines. <i>Journal of Experimental and Clinical Cancer Research</i> , 2009, 28, 146.	8.6	18
76	CIGB-300, a novel proapoptotic peptide that impairs the CK2 phosphorylation and exhibits anticancer properties both in vitro and in vivo. <i>Molecular and Cellular Biochemistry</i> , 2008, 316, 163-167.	3.1	86
77	Systemic administration of a peptide that impairs the protein kinase (CK2) phosphorylation reduces solid tumor growth in mice. <i>International Journal of Cancer</i> , 2008, 122, 57-62.	5.1	64
78	Perioperative desmopressin prolongs survival in surgically treated bitches with mammary gland tumours: A pilot study. <i>Veterinary Journal</i> , 2008, 178, 103-108.	1.7	32
79	Enhanced cytostatic activity of statins in mouse mammary carcinoma cells overexpressing $\beta$ 2-chimaerin. <i>Molecular Medicine Reports</i> , 2008, 2, 97-102.	2.4	7
80	Molecular detection of circulating tyrosinase mRNA: optimization in a preclinical xenograft mouse melanoma model and further evaluation in samples from advanced melanoma patients. <i>International Journal of Molecular Medicine</i> , 2008, 21, 555-9.	4.0	2
81	Antitumor effects of desmopressin in combination with chemotherapeutic agents in a mouse model of breast cancer. <i>Anticancer Research</i> , 2008, 28, 2607-11.	1.1	16
82	1E10 anti-idiotypic vaccine in non-small cell lung cancer: Experience in stage IIIb/IV patients.. <i>Cancer Biology and Therapy</i> , 2007, 6, 1847-1852.	3.4	63
83	Active immunotherapy with 1E10 anti-idiotypic vaccine in patients with small cell lung cancer: Report of a phase I trial. <i>Cancer Biology and Therapy</i> , 2007, 6, 145-150.	3.4	75
84	T cells are crucial for the anti-metastatic effect of anti-epidermal growth factor receptor antibodies. <i>Cancer Immunology, Immunotherapy</i> , 2007, 56, 1701-1710.	4.2	43
85	Complete Antitumor Protection by Perioperative Immunization with GM3/VSSP Vaccine in a Preclinical Mouse Melanoma Model. <i>Clinical Cancer Research</i> , 2006, 12, 7092-7098.	7.0	21
86	Desmopressin and other synthetic vasopressin analogues in cancer treatment. <i>Bulletin Du Cancer</i> , 2006, 93, E7-12.	1.6	4
87	Antitumor and antiangiogenic activity of soy isoflavone genistein in mouse models of melanoma and breast cancer. <i>Oncology Reports</i> , 2006, 16, 885-91.	2.6	109
88	Desmopressin reduces melanoma lung metastasis in transgenic mice overexpressing tissue inhibitor of metalloproteinases-1. <i>In Vivo</i> , 2006, 20, 881-5.	1.3	7
89	Role of beta2-chimaerin in the behaviour of murine mammary carcinoma cells in response to extracellular matrix components. <i>International Journal of Molecular Medicine</i> , 2005, 15, 91-5.	4.0	2
90	Antitumor Effect of a Novel Proapoptotic Peptide that Impairs the Phosphorylation by the Protein Kinase 2 (Casein Kinase 2). <i>Cancer Research</i> , 2004, 64, 7127-7129.	0.9	139

#	ARTICLE	IF	CITATIONS
91	7A7 MAb: A New Tool for the Pre-Clinical Evaluation of EGFR-Based Therapies. Hybridoma, 2004, 23, 168-175.	0.4	26
92	Active Specific Immunotherapy of Melanoma with a GM3 Ganglioside-Based Vaccine. Journal of Immunotherapy, 2004, 27, 442-451.	2.4	39
93	Role of protein kinase C-dependent signaling pathways in the antiangiogenic properties of nafoxidine. Anticancer Research, 2004, 24, 1737-43.	1.1	2
94	Ganglioside-based vaccines and anti-idiotypic antibodies for active immunotherapy against cancer. Expert Review of Vaccines, 2003, 2, 817-823.	4.4	30
95	Inhibition of aggressiveness of metastatic mouse mammary carcinoma cells by the beta2-chimaerin GAP domain. Cancer Research, 2003, 63, 2284-91.	0.9	39
96	Desmopressin inhibits lung and lymph node metastasis in a mouse mammary carcinoma model of surgical manipulation. Journal of Surgical Oncology, 2002, 81, 38-44.	1.7	36
97	Role of cell surface GM3 ganglioside and sialic acid in the antitumor activity of a GM3-based vaccine in the murine B16 melanoma model. Journal of Cancer Research and Clinical Oncology, 2002, 128, 669-677.	2.5	8
98	Lovastatin alters cytoskeleton organization and inhibits experimental metastasis of mammary carcinoma cells. Clinical and Experimental Metastasis, 2002, 19, 551-560.	3.3	58
99	Cancer vaccines: an update with special focus on ganglioside antigens. Oncology Reports, 2002, 9, 267-76.	2.6	60
100	A purified GM3 ganglioside conjugated vaccine induces specific, adjuvant-dependent and non-transient antitumour activity against B16 mouse melanoma in vitro and in vivo. Melanoma Research, 2001, 11, 219-227.	1.2	27
101	Chronic In Vitro Exposure to 3- $\beta$ -Azido-2- $\beta$ -Dideoxythymidine Induces Senescence and Apoptosis and Reduces Tumorigenicity of Metastatic Mouse Mammary Tumor Cells. Breast Cancer Research and Treatment, 2001, 65, 93-99.	2.5	36
102	In Vitro Activity of a Solanum tuberosum Extract against Mammary Carcinoma Cells. Planta Medica, 2001, 67, 164-166.	1.3	5
103	Antimetastatic effect of desmopressin in a mouse mammary tumor model. Breast Cancer Research and Treatment, 1999, 57, 271-275.	2.5	32
104	Deregulation of the signaling pathways controlling urokinase production. Its relationship with the invasive phenotype. FEBS Journal, 1999, 263, 295-304.	0.2	170
105	Modulation of urokinase-type plasminogen activator and metalloproteinase activities in cultured mouse mammary-carcinoma cells: Enhancement by paclitaxel and inhibition by nocodazole. , 1999, 83, 242-246.		11
106	Role of Tumor-Derived Granulocyte-Macrophage Colony-Stimulating Factor in Mice Bearing a Highly Invasive and Metastatic Mammary Carcinoma. Pathobiology, 1999, 67, 180-185.	3.8	10
107	Reduction of mouse mammary tumor formation and metastasis by lovastatin, an inhibitor of the mevalonate pathway of cholesterol synthesis. Breast Cancer Research and Treatment, 1998, 50, 83-93.	2.5	135
108	Secretion of urokinase and metalloproteinase-9 induced by staurosporine is dependent on a tyrosine kinase pathway in mammary tumor cells. , 1998, 76, 362-367.		10



#	ARTICLE	IF	CITATIONS
109	Overproduction of urokinase-type plasminogen activator is regulated by phospholipase D- and protein kinase C-dependent pathways in murine mammary adenocarcinoma cells. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 1997, 1356, 171-184.	4.1	14
110	A phospholipase D and protein kinase C inhibitor blocks the spreading of murine mammary adenocarcinoma cells altering f-actin and $\beta$ 1-integrin point contact distribution. , 1997, 71, 881-890.		20
111	Excessive urokinase-type plasminogen activator activity in the euglobulin fraction of patients with Alzheimer-type dementia. <i>Journal of the Neurological Sciences</i> , 1996, 139, 83-88.	0.6	11
112	Effects of synthetic urokinase inhibitors on local invasion and metastasis in a murine mammary tumor model. <i>Breast Cancer Research and Treatment</i> , 1996, 40, 209-223.	2.5	58
113	Characterization of F3II, a sarcomatoid mammary carcinoma cell line originated from a clonal subpopulation of a mouse adenocarcinoma. <i>Journal of Surgical Oncology</i> , 1996, 62, 288-297.	1.7	47
114	Varying patterns of expression of insulin-like growth factors I and II and their receptors in murine mammary adenocarcinomas of different metastasizing ability. , 1996, 65, 812-820.		37
115	Characterization of F3II, a sarcomatoid mammary carcinoma cell line originated from a clonal subpopulation of a mouse adenocarcinoma. , 1996, 62, 288.		1
116	Effect of Host-Organ Environment on the in vivo and in vitro Behavior of a Murine Mammary Adenocarcinoma. <i>Tumor Biology</i> , 1994, 15, 284-293.	1.8	6
117	Impairment of fibrinolysis during the growth of two murine mammary adenocarcinomas. <i>Cancer Letters</i> , 1993, 70, 181-187.	7.2	19
118	Soluble factors released by the target organ enhance the urokinase-type plasminogen activator activity of metastatic tumor cells. <i>Clinical and Experimental Metastasis</i> , 1991, 9, 51-56.	3.3	14
119	States of stability/lysis in human fetal and adults red blood cells. <i>Archives Internationales De Physiologie Et De Biochimie</i> , 1989, 97, 309-316.	0.2	11
120	Function and Expression of the uPA/uPAR System in Cancer Metastasis. , 0, , 223-236.		1